search
Back to results

A Single-patient Study of Repeat-dose Administration of Prometic Plasminogen (Human) Intravenous

Primary Purpose

Hypoplasminogenemia

Status
No longer available
Phase
Locations
Study Type
Expanded Access
Intervention
Plasminogen (Human)
Sponsored by
Prometic Biotherapeutics, Inc.
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an expanded access trial for Hypoplasminogenemia

Eligibility Criteria

16 Months - undefined (Child, Adult, Older Adult)All Sexes

Inclusion Criteria:

  • Patient has provided informed consent.
  • Patient has a diagnosis of compound homozygous Type 1 plasminogen deficiency as evidence by ligneous conjunctivitis since birth as well as involvement of the conjunctiva, nasopharynx, gingiva, tracheobronchial tree, gastrointestinal tract, and urinary tract.

Exclusion Criteria:

  • Not applicable

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Secondary Outcome Measures

    Full Information

    First Posted
    August 25, 2017
    Last Updated
    April 22, 2020
    Sponsor
    Prometic Biotherapeutics, Inc.
    Collaborators
    Cedars-Sinai Medical Center, Vanderbilt University Medical Center, Indiana Hemophilia &Thrombosis Center, Inc.
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03265171
    Brief Title
    A Single-patient Study of Repeat-dose Administration of Prometic Plasminogen (Human) Intravenous
    Official Title
    A Single-patient Study of Repeat-dose Administration of ProMetic Plasminogen (Human) Intravenous Infusion in an Adult With Hypoplasminogenemia
    Study Type
    Expanded Access

    2. Study Status

    Record Verification Date
    April 2020
    Overall Recruitment Status
    No longer available
    Study Start Date
    undefined (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Prometic Biotherapeutics, Inc.
    Collaborators
    Cedars-Sinai Medical Center, Vanderbilt University Medical Center, Indiana Hemophilia &Thrombosis Center, Inc.

    4. Oversight

    5. Study Description

    Brief Summary
    These are single-patient studies with repeat-dose administration of ProMetic Plasminogen IV infusion in one adult and one child with hypoplasminogenemia. These patients are under treatment to address wound healing and obstructions.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hypoplasminogenemia

    7. Study Design

    8. Arms, Groups, and Interventions

    Intervention Type
    Biological
    Intervention Name(s)
    Plasminogen (Human)

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    16 Months
    Eligibility Criteria
    Inclusion Criteria: Patient has provided informed consent. Patient has a diagnosis of compound homozygous Type 1 plasminogen deficiency as evidence by ligneous conjunctivitis since birth as well as involvement of the conjunctiva, nasopharynx, gingiva, tracheobronchial tree, gastrointestinal tract, and urinary tract. Exclusion Criteria: Not applicable

    12. IPD Sharing Statement

    Learn more about this trial

    A Single-patient Study of Repeat-dose Administration of Prometic Plasminogen (Human) Intravenous

    We'll reach out to this number within 24 hrs